What is GH Research PLC?
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States.
The story behind the price, the case for and against, and what could go wrong. Open a part to read it.
GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.20B.
A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.